HomeInvesting NewsPacira Achieves Major Objectives, In a Late-Stage Experiment to Broaden the Indication...

Pacira Achieves Major Objectives, In a Late-Stage Experiment to Broaden the Indication for Local Anesthetics.

Published on

In 96 hours, the study’s major and important secondary endpoints—statistically substantial decreases in postsurgical pain and opioid consumption—were met.

Pacira BioSciences (NASDAQ:PCRX)

Pacira BioSciences (NASDAQ:PCRX), a company specializing in non-opioid pain management, said Wednesday that the primary endpoint of a Phase 3 trial for its top product, Exparel, had been met. This has enabled the business to pursue label expansion for the local anesthetic.

The randomized experiment compares the effectiveness of Exparel with bupivacaine HCl when given as a femoral nerve block in a person’s adductor canal and in patients having total knee arthroplasty.

In the multicenter experiment, 166 participants were randomly assigned to receive either Exparel mixed with the local anesthetic bupivacaine HCl or bupivacaine HCl mixed with ordinary saline.

Topline findings demonstrate that Exparel met the primary aim of the study by statistically significantly reducing overall pain scores from 0 to 96 hours when compared to bupivacaine HCl. The trial also met a crucial secondary aim by showing a statistically significant decrease in postsurgical opioid usage through 96 hours compared with bupivacaine HCl.

“We believe we are now in a good position to expand the EXPAREL label to include an additional indication for nerve blocks and further establish EXPAREL as a cornerstone in opioid-sparing postsurgical pain treatment regimens,” the company claims. Pacira’s CEO, Dave Stack, said in a statement. 

To request a label expansion for Exparel to include the new indication, Pacira anticipates submitting a supplemental New Drug Application to the FDA early in the following year. The business has not yet submitted the data for publication in a peer-reviewed journal.

Results

For the month of July 2022, Pacira reported initial unaudited net product sales of $50.2 million. COVID-19 and pandemic-related problems have had an impact on the company’s earnings, including the large postponement or suspension of the scheduling of elective surgical procedures as a result of government orders and public health guidelines. $506.5 million in A total of $506.5les from Exparel were reported by Pacira in 2021, representing a 23% YoY rise.

Featured Image-  Megapixl @7activestudio

Please See Disclaimer

Latest News

Recent Surge in Tesla Stock: Exactly What Caused It?

Tesla Stock (NASDAQ:TSLA) As of 11:30 a.m ET on Friday, Tesla stock was up 2.3%...

Here’s Why Carvana Stock Fell Quite So Much as 23.7% This Week

Carvana Stock (NYSE:CVNA) According to data provided by S&P Global Market Intelligence, Carvana stock fell...

Here’s Why Tellurian Stock Is Rising Again Today

Tellurian Stock (NYSEMKT:TELL) Tellurian stock was up 6.5% as of 11:06 p.m. ET today after...

Is It Time to Buy Chewy Stock?

Chewy Stock (NYSE:CHWY) Pet supplies are one of the few consumer goods that do well,...

More like this

2 Casino Stocks You Should Consider

With a recession on the horizon, investors must be more selective than ever. Analysts...

(Exxon Mobil Stock) Exxon Ceo Warns Biden Administration Against Restricting Fuel Exports

Exxon (Exxon Mobil Stock) opposes calls for oil corporations to reduce international exports and...

Apple Stock Loses $120 Billion Because of a Rare Downgrade

Apple stock just took a significant knock after it was once considered to be...

Meta Stock Tops Morningstar List of the Most Undervalued Stocks 

Morningstar compiled a list of the most undervalued stocks among those with a large...

Hd Stock up as Foundation to Contribute Up to $1 Million to Aid Communities Affected by Hurricane Ian

HD stock was trading at $280.23 as of 12:55 PM EDT. The Home Depot Foundation...

Making the Cut: Micron (Micron Stock)

Micron Technology Inc (Micron Stock) latest outlook brings expectations back to normal, although the...